Klotho Neurosciences (KLTO) CEO granted 2.5M new shares

Rhea-AI Filing Summary

Klotho Neurosciences, Inc. reported that Chief Executive Officer Joseph Sinkule acquired 2,500,000 shares of common stock on March 4, 2026 through a grant under the company’s Equity Incentive Plan. The shares were reported at a price of $0.00 per share.

Following this grant, Sinkule’s directly held common stock increased to 6,346,700 shares. This transaction reflects an equity award rather than an open-market purchase or sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SINKULE JOSEPH

(Last) (First) (Middle)

1300 SOUTH BOULEVARD SUITE D

(Street)

CHARLOTTE NC 28203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Klotho Neurosciences, Inc. [ KLTO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		2,500,000	A	(1)	6,346,700	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting person received the shares as a grant under the company's Equity Incentive Plan.

Remarks:

	Joseph Sinkule	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Klotho Neurosciences (KLTO) report for Joseph Sinkule?

Klotho Neurosciences reported that CEO Joseph Sinkule received a grant of 2,500,000 shares of common stock. The award was made under the company’s Equity Incentive Plan and reflects an equity grant, not an open-market stock purchase or sale.

How many Klotho Neurosciences (KLTO) shares did the CEO hold after this Form 4 transaction?

After the equity grant, CEO Joseph Sinkule directly held 6,346,700 shares of Klotho Neurosciences common stock. This total includes the newly granted 2,500,000 shares reported in the filing for the March 4, 2026 award.

Was the Klotho Neurosciences (KLTO) CEO’s 2,500,000-share award an open-market purchase?

No, the 2,500,000-share increase for CEO Joseph Sinkule came from a grant under the company’s Equity Incentive Plan. The reported transaction price was $0.00 per share, indicating an equity award rather than a market purchase.

What transaction code was used in the Klotho Neurosciences (KLTO) Form 4 filing?

The transaction was reported with code “A,” which indicates a grant, award, or other acquisition of securities. This aligns with the footnote stating the CEO received the shares as a grant under the Equity Incentive Plan.

Does the Klotho Neurosciences (KLTO) Form 4 show direct or indirect ownership for the new shares?

The filing reports the 2,500,000 newly granted shares as directly owned by CEO Joseph Sinkule. The ownership code is listed as “D” for direct, with no additional indirect ownership entity described in the footnotes.